Effects of probiotic yogurt consumption on intestinal permeability in inflammatory bowel disease: A double-blind randomized clinical Trial

authors:

avatar Mahdi Shadnoush ORCID , avatar Maryam Nazari , avatar Hossein Hajianfar , avatar zeinab faghfoori ORCID , *

Koomesh: Vol.23, issue 2; 211-217
published online: May 01, 2021
article type: Research Article
received: April 02, 2020
accepted: October 01, 2020

how to cite: Shadnoush M, Nazari M, Hajianfar H, faghfoori Z. Effects of probiotic yogurt consumption on intestinal permeability in inflammatory bowel disease: A double-blind randomized clinical Trial. koomesh. 2021;23(2):e153258. 

Abstract

Introduction: Disorders in intestinal permeability have been reported in the pathophysiology of inflammatory bowel diseases (IBD) that may be compensated by complementary therapies through modifying the composition of the intestinal microflora. This study was designed to evaluate the effect of probiotic yogurt on intestinal permeability in patients with IBD. Materials and Methods: In this double-blind randomized clinical trial, 86 patients in the probiotic yogurt group (intervention patient), 90 patients in the plain yogurt group (control patient) and 84 volunteers in healthy control group  receiving 250 g of commercial probiotic/plain yogurt daily for 8 weeks. At the end of the eighth week, a lactulose/mannitol ratio (LMR) test was used to assess intestinal permeability. Results: The mean age of participants in the study was 37.7 years and the mean body mass index in all subjects was 24.17 ± 2.65 kg/ m2. There was no significant difference in the LMR of the intervention group and control patient group at the beginning of the study (P=0.08) However, at the end of the period, this ratio decreased significantly in the intervention group compared to the control patient group (P=0.023). Importantly, this indicator in the healthy control group in comparison with intervention group was significantly lower at the beginning and at the end of the study. Conclusion: The results of the present study showed that probiotics consumption via diet such as its use in dairy products such as yogurt can be a good way to improve gastrointestinal damage, including improving the permeability of the intestine and prevent or repair mucosal damage.  

References

  • 1.

    Halloran K, Underwood MA. Probiotic mechanisms of action. Early Hum Dev 2019; 135: 58-65.

  • 2.

    Michielan A, D'Inc R. Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut. Mediat Inflamm 2015; 2015: 628157.

  • 3.

    Mike G Laukoetter, Porfirio Nava, Asma Nusrat Role of the intestinal barrier in inflammatory bowel disease. World J Gastroenterol 2008; 14: 401-407.

  • 4.

    Benjamin J, Makharia G, Ahuja V, Kalaivani M, K Joshi Y. Intestinal permeability and its association with the patient and disease characteristics in Crohn's disease. World J Gastroenterol 2008; 14: 1399-1405.

  • 5.

    Hanauer S. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006; 12: S3-S9.

  • 6.

    Fava F, Danese S. Intestinal microbiota in inflammatory bowel disease: Friend of foe? World J Gastroenterol 2011; 17: 557-566.

  • 7.

    Head KA, Jurenka JS. Inflammatory bowel disease Part 1: ulcerative colitis--pathophysiology and conventional and alternative treatment options. Altern Med Rev 2003; 8: 247-283.

  • 8.

    Meijer BJ, Dielema LA. Probiotics in the treatment of human inflammatory bowel diseases. J Clin Gastroenterol 2011; 45: S139-S144.

  • 9.

    Schultz M, Veltkamp C, Dieleman LA, Grenther WB, Wyrick PB, Tonkonogy SL, et al. Lactobacillus plantarum 299v in the treatment and prevention of spontaneous colitis in Interleukin-10- deficient mice. Inflamm Bowel Dis 2002; 8: 71-80.

  • 10.

    Youssef L, Francis M, Mladenovic A, Geagea AG, Cehovin K, Saleh H, et al. Probiotics: In Sickness and In Health. Int J Recent Sci Res 2018; 9: 192-203.

  • 11.

    McCarthy J, O,Mahony L, O,Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, et al. Double blind, placebo-controlled trial of two probiotic strains in IL-10 knockout mice and mechanistic links with cytokine balance. Gut 2003; 52: 975-980.

  • 12.

    Malin M, Suomalainen H, Saxelin M, Isolauri E. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 1996; 40: 137-145.

  • 13.

    Garcia Vilela E, De Lourdes De Abreu Ferrari M, Oswaldo Da Gama Torres H, Guerra Pinto A, Carolina Carneiro Aguirre A, Paiva Martins F, et al. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol 2008; 43: 842-848.

  • 14.

    Zhang CX, Wang HY, Chen TX. Interactions between intestinal microflora/probiotics and the immune system. Biomed Res Int 2019; 2019: 6764919.

  • 15.

    Hedin C, Whelan K, Lindsay JO. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc 2007; 66: 307-315.

  • 16.

    Mishima Y, Sartor RB. Manipulating resident microbiota to enhance regulatory immune function to treat inflammatory bowel diseases. J Gastroenterol 2020; 55: 4-14.

  • 17.

    Haas V, Bning C, Buhner S, von Heymann C, Valentini L, Lochs H. Clinical relevance of measuring colonic permeability. Eur J Clin Invest 2009; 39: 139-144.

  • 18.

    Poritz LS, Garver KI, Green C, Fitzpatrick L, Ruggiero F, Koltun WA. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. J Surg Res 2007; 140: 12-19.

  • 19.

    Bning C, Geissler N, Prager M, Sturm A, Baumgart DC, Bttner J, et al. Increased small intestinal permeability in ulcerative colitis: rather genetic than environmental and a risk factor for extensive disease? Inflamm Bowel Dis 2012; 18: 1932-1939.

  • 20.

    Welcker K, Martin A, Klle P, Siebeck M, Gross M. Increased intestinal permeability in patients with inflammatory bowel disease. Eur J Med Res 2004; 9: 456-460.

  • 21.

    Shadnoush M, Shaker Hosseini R, Khalilnezhad A, Navai L, Goudarzi H ,Vaezjalali M. Effects of probiotics on Gut microbiota in patients with inflammatory bowel disease: a double-blind, placebo-controlled clinical trial. Korean J Gastroenterol 2015; 65: 215-222.

  • 22.

    Shen L, Su L, Turner JR. Mechanisms and functional implications of intestinal barrier defects. Dig Dis 2009; 27: 443-449.

  • 23.

    Laukoetter MG, Nava P, Nusrat A. Role of the intestinal barrier in inflammatory bowel disease. World J Gastroenterol 2008; 14: 401-407.

  • 24.

    Mankertz J, Schulzke JD. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. Curr Opin Gastroenterol 2007; 23: 379-383.

  • 25.

    Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2009; 15: 300-310.

  • 26.

    Hartstra AV, Nieuwdorp M, Herrema H. Interplay between gut microbiota, its metabolites and human metabolism: Dissecting cause from consequence. Trends Food Sci Tech 2016; 57: 233-243.##https://doi.org/10.1016/j.tifs.2016.08.009.

  • 27.

    Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003; 52: 988-997.

  • 28.

    Devi SM, Archer AC, Halami PM. Screening, characterization and in vitro evaluation of probiotic properties among lactic acid bacteria through comparative analysis. Probiotics Antimicrob 2015; 7: 181-192.

  • 29.

    Gill HS. Probiotics to enhance anti-infective defences in the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2003; 17: 755-773.##https://doi.org/10.1016/S1521-6918(03)00074-X.

  • 30.

    Fioramonti J, Theodorou V, Bueno L. Probiotics: what are they? What are their effects on gut physiology? Best Pract Res Clin Gastroenterol 2003; 17: 711-724.##https://doi.org/10.1016/S1521-6918(03)00075-1.